Minim MINM 深 沪
已收盘 07-09 16:00:00 美东时间
3.61
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 3.61
- 总市值 1.67亿
- 52周最高 10.28
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.55
- 委 比 0.00%
- 总股本 4629.70万
- 历史最高 14.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.02
- 每 手 1
- 风险率 0.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Palvella: 73% Improved In Phase 2 Study Of Skin Condition Treatment
Palvella Therapeutics reports Phase 2 data showing 73% improvement with QTORIN rapamycin gel in cutaneous venous malformations.
12-16 00:50
Reddit Files Lawsuit Against Australia's Under-16 Social Media Ban Citing Free Speech Violation
Reddit (NASDAQ: RDDT) has taken legal action against Australia's ban on social media for under-16s, arguing that it infringes on free political discourse.
12-12 16:12
Retail Investors Remain Bullish As Wall Street Eyes Strong Finish
Retail investors are upbeat about the stock market's near-term prospects, despite lingering uncertainty around the Fed policy outlook.
12-12 00:14
Why Did Clearmind Medicine Shares Plunge 29% After Hours?
Clearmind Medicine shares dropped in after-hours trading following the company's announcement of a 1-for-40 reverse stock split.
12-11 16:28
Hess Midstream Forecasts $650M–$700M Net Income, $1.25B Adjusted EBITDA, $850M–$900M Adjusted Free Cash Flow For 2026
Hess Midstream LP (NYSE:HESM) ("Hess Midstream") today provided financial and operational guidance and expectations."We continue to successfully execute our strategy of delivering safe and reliable execution," said
12-09 20:36
Lululemon Runs Into Tariff Trouble While Racing To Refresh Core Collections
Lululemon's third-quarter report faces slowing sales growth, margin squeeze from tariffs, and weaker U.S. demand.
12-09 01:42
Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start
FDA placed hold on Denali's drug for Pompe disease, requesting changes to protocol. No additional studies requested. Minimal delays expected.
12-06 00:49
Intensity Therapeutics Granted 180-Day Extension To Regain Nasdaq Compliance
Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to
12-05 20:31
Workhorse Group Approves 1-For-12 Reverse Stock Split, Effective December 8
As previously disclosed, on November 25, 2025, the stockholders of Workhorse Group Inc. (the "Company") approved a proposal authorizing the Board of Directors of the Company (the "Board") to effect a reverse stock split
12-04 05:54
Fractyl Health's Revita Procedure Helps Patients Keep Weight Off After Stopping GLP-1 Drugs
Fractyl Health (NASDAQ: GUTS) released positive 6-month results from its REVEAL-1 study in obese patients who discontinued GLP-1 therapy.
12-03 01:28
